Lifecome Biochemistry Co Ltd (002868) - Total Assets
Based on the latest financial reports, Lifecome Biochemistry Co Ltd (002868) holds total assets worth CN¥1.38 Billion CNY (≈ $202.56 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Lifecome Biochemistry Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Lifecome Biochemistry Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Lifecome Biochemistry Co Ltd's total assets have evolved over time, based on quarterly financial data.
Lifecome Biochemistry Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Lifecome Biochemistry Co Ltd's total assets of CN¥1.38 Billion consist of 14.5% current assets and 85.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 1.7% |
| Accounts Receivable | CN¥79.80 Million | 5.4% |
| Inventory | CN¥95.71 Million | 6.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥125.58 Million | 8.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Lifecome Biochemistry Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Lifecome Biochemistry Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lifecome Biochemistry Co Ltd's current assets represent 14.5% of total assets in 2024, a decrease from 28.4% in 2012.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2024, down from 4.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 2.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 8.4% of total assets.
Lifecome Biochemistry Co Ltd Competitors by Total Assets
Key competitors of Lifecome Biochemistry Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Lifecome Biochemistry Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.15 | 0.33 | 2.40 |
| Quick Ratio | 0.06 | 0.15 | 1.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-1.09 Billion | CN¥-485.28 Million | CN¥177.76 Million |
Lifecome Biochemistry Co Ltd - Advanced Valuation Insights
This section examines the relationship between Lifecome Biochemistry Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.51 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | -24.1% |
| Total Assets | CN¥1.49 Billion |
| Market Capitalization | $882.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lifecome Biochemistry Co Ltd's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lifecome Biochemistry Co Ltd's assets decreased by 24.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lifecome Biochemistry Co Ltd (2012–2024)
The table below shows the annual total assets of Lifecome Biochemistry Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.49 Billion ≈ $218.28 Million |
-24.09% |
| 2023-12-31 | CN¥1.97 Billion ≈ $287.54 Million |
+58.49% |
| 2022-12-31 | CN¥1.24 Billion ≈ $181.43 Million |
-1.47% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.14 Million |
+29.40% |
| 2020-12-31 | CN¥972.50 Million ≈ $142.31 Million |
-3.72% |
| 2019-12-31 | CN¥1.01 Billion ≈ $147.80 Million |
+25.88% |
| 2018-12-31 | CN¥802.42 Million ≈ $117.42 Million |
+6.11% |
| 2017-12-31 | CN¥756.25 Million ≈ $110.66 Million |
+104.03% |
| 2016-12-31 | CN¥370.66 Million ≈ $54.24 Million |
-5.57% |
| 2015-12-31 | CN¥392.52 Million ≈ $57.44 Million |
+0.62% |
| 2014-12-31 | CN¥390.09 Million ≈ $57.08 Million |
-1.46% |
| 2013-12-31 | CN¥395.88 Million ≈ $57.93 Million |
+6.60% |
| 2012-12-31 | CN¥371.37 Million ≈ $54.34 Million |
-- |
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, photovoltaic film products, etc.; veterinary drugs; and food preservatives. The company was founded in 2003 and is based in Pucheng, China.